Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

NCT02784158 is registered in ClinicalTrials.gov with Ariad Pharmaceuticals as lead sponsor.

NCT NCT02784158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02784158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Lead sponsor
Ariad Pharmaceuticals
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, carcinoma, lung cancer, non-small cell lung cancer